Nerve growth factor delivery systems

Journal of Controlled Release

Volumn 53, Issue 1-3, 1998, Pages 1-6

  Haller, Michael F ^a   Saltzman, W Mark ^a  

^a Cornell University   (United States)

Author keywords

Alzheimer's disease; Cell transplantation; Controlled release; Epidermal growth factor; Growth factors; Morphogen; Nerve growth factor; Polymer

Indexed keywords

BIOMATERIAL; MICROSPHERE; NERVE GROWTH FACTOR; POLYMER;

ALZHEIMER DISEASE; BIOCOMPATIBILITY; CELL TRANSPLANTATION; CONFERENCE PAPER; CONTROLLED RELEASE FORMULATION; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; GENETIC ENGINEERING; HUMAN; NERVE CELL DEGENERATION; NERVE REGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION;

ANIMALS; CELL TRANSPLANTATION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NERVE GROWTH FACTORS; NEURODEGENERATIVE DISEASES; POLYMERS;

EID: 0032580449     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(97)00232-0     Document Type: Conference Paper

References (54)

1. De Robertis E.M., Morita E.A., Cho K.W.Y. Gradient fields and homeobox genes. Development. 112:1991;669-678.
2. Risau W., Flamme I. Ann. Rev. Cell Dev. Biol. 11:1995;73-91.
3. Driever W., Nusslein-Volhard C. The bicoid protein determines position in the drosophila embryo in a concentration-dependent manner. Cell. 54:1988;95-104.
4. St. Johnston D., Nusslein-Volhard C. The origin of pattern and polarity in the drosophila embryo. Cell. 68:1992;201-219.
5. Prigent S.A., Lemoine N.R. The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog. Growth Factor Res. 4(1):1992;1-24.
6. Schultz G.S., White M., Mitchell R., Brown G., Lynch J., Twardzik D.R., Todaro G.J. Epithelial wound healing enhanced by transforming growth factor alpha and vaccinia growth factor. Science. 235:1987;350-352.
7. Szabo S., Sandor Z. Basic fibroblast growth factor and PDGF in GI diseases. Baillieres Clin. Gastroenterol. 10(1):1996;97-112.
8. Dreyfus C.F. Effects of nerve growth factor on cholinergic brain neurons. TiPS. 10:1989;145-149.
9. Levi-Montalcini R., Skaper S., Dal Toso R., Petrellli L., Leon A. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci. 19(11):1996;514-520.
10. Craig C., Morshead T.V.C., Reynolds B., Weiss S., van der Kooy D. In vivo growth factor expansion of endogenous subependymal neural precursor cell populations in the adult mouse brain. J. Neurosci. 16(8):1996;2649-2658.
11. Aaronson S.A. Growth factors and cancer. Science. 254:1991;1146-1153.
12. Yasui W., Hata J., Yokozaki H., Nakatani H., Ochiai A., Ito H., Tahara E. Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma. Int. J. Cancer. 41:1988;211-217.
13. Libermann T.A., Nusbaum H.R., Razon N., Kris R., Lax I., Soreq H., Whittle N., Waterfield M.D., Ullrich A., Schlessinger J. Amplification, enhanced expression and possible rearrangement of the EGF receptor gene in primary human brain tumours of glial origin. Nature. 313:1985;144-147.
14. Klijn J.G., Berns P.M., Schmitz P.I., Foekens J.A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocrine Rev. 13(1):1992;3-17.
15. Ekstrand A.J., James C.D., Cavenee W.K., Seliger B., Pettersson R.F., Collins V.P. Genes for epidermal growth factor receptor, transforming grouwth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 51:1991;2164-2172.
16. Maxwell M., Naber S.P., Wolfe H.J., Galanopoulos E.T. Antoniades, Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J. Clin. Invest. 86:1990;131-140.
17. Fleming T.P., Matsui T., Molloy C.J., Robbins K.C., Aaronson S.A. Autocrine mechanism for v-sis transformation requires cell surface localization of internally activated grwoth factor receptors. Proc. Natl. Acad. Sci. 86:1989;8063-8067.
18. Akiyama S.I., Gottesman M.M., Hanorver J.A., Fitzgerald D.J.P., Willingham M.C., Pastan I. Verapamil enhances the toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin and antitransferrin receptor with Pseudomonas exotoxin. J. Cell. Physiol. 120:1984;271-279.
19. Olsson P., Lindstrom A., Carlsson J. Internalization and excretion of epidermal growth factor-dextran-associated radioactivity in cultured human squamous-carcinoma cells. Int. J. Cancer. 56(4):1994;529-537.
20. Theuer C.P., FitzGerald D., Pastan I. A recombinant form of Pseudomonas extoxin directed at the epidermal growth factor receptor that is cytotoxic without requiring proteolytic processing. J. Biol. Chem. 267(24):1992;16872-16877.
21. Faillot T., Magdelenat H., Mady E., Stasiecki P., Fohanno D., Gropp P., Poisson M., Delattre J.Y. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery. 39(3):1996;478-483.
22. Kim D.C., Sugiyama Y., Satoh H., Fuwa T., Iga T., Hanano M. Kinetic analysis of in vivo receptor-dependent binding of human epidermal growth factor by rat tissues. J. Pharm. Sci. 77(3):1988;200-207.
23. Konturek S.J., Pawlik W., Mysh W., Gustaw P., Sendur R., Mikos E., Bielanski W. Comparison of organ uptake and disappearance half time of human epidermal growth factor and insulin. Regul. Pept. 30:1990;137-148.
24. Edelman E.R., Nugent M.A., Karnovsky M.J. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc. Natl. Acad. Sci. US. 90(4):1993;1513-1517.
25. Saltzman W.M., Radomsky M.L. Drugs released from polymers: diffusion and elimination in brain tissue. Chem. Eng. Sci. 46(10):1991;2429-2444.
26. Strasser J.F., Fung L.K., Eller S., Grossman S.A., Saltzman W.M. Distribution of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and tracers in the rabbit brain after interstitial delivery by biodegradable polymer implants. J. Pharmacol. Exp. Ther. 275(3):1995;1647-1655.
27. Fung L.K., Shin M., Tyler B., Brem H., Saltzman W.M. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm. Res. 13(5):1996;671-682.
28. M.W. Mak, Ph.D. thesis, Controlled delivery of recombinant human growth factor (rhNGF) to the brain interstitium by biodegradable polymers, The Johns Hopkins University, 1996, p. 199.
29. C.E. Krewson, Ph.D. thesis, Controlled delivery of growth factors and cells for the treatment of neurodegenerative disorders, The Johns Hopkins University, 1996, p. 312.
30. Brem H., Piantadosi S., Burger P.C., Walker M., Selker R., Vick N.A., Black K., Sisti M., Brem S., Mohr G., Muller P., Morawetz R., Schold S.C. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 345:1995;1008-1012.
31. Powell E.M., Sobarzo M.R., Saltzman W.M. Controlled release of nerve growth factor from a polymeric implant. Brain Res. 515:1990;309-311.
32. Krewson C.E., Klarman M.L., Saltzman W.M. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res. 680:1995;196-206.
33. Krewson C.E., Saltzman W.M. Transport and elimination of recombinant human NGF during long-term delivery to the brain. Brain Res. 727:1996;169-181.
34. Dang W., Saltzman W.M. Dextran retention in the rat brain following releasefrom a polymer implant. Biotechnol. Prog. 8:1992;527-532.
35. Dang W., Colvin O.M., Brem H., Saltzman W.M. Covalent coupling of methotrexate to dextran enhances the penetration of cytotoxicity into a tissue-like matrix. Cancer Res. 54:1994;1729-1735.
36. Krewson C.E., Dause R., Mak M., Saltzman W.M. Stabilization of nerve growth factor in controlled release polymers and in tissue. J. Biomat. Sci., Polymer Ed. 8(2):1996;103-117.
37. Kordower J.H., Freeman T.B., Snow et al B.J. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N. Engl. J. Med. 332(17):1995;1118-1124.
38. Spencer D.D., Robbins R.J., Naftolin et al F. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N. Engl. J. Med. 327(22):1992;1541-1548.
39. Widner H., Tetrud J., Rehncrona et al S. Bilateral fetal mesencephalic grafting in two patients with Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydrophyridine (MPTP). N. Engl. J. Med. 327(22):1992;1556-1563.
40. Freed C.R., Breeze R.E., Rosenberg et al N.L. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N. Engl. J. Med. 327(22):1992;1549-1555.
41. Kordower J.H., Rosenstein J.M., Collier et al T.J. Functional fetal nigral grafts in a patient with Parkinson's Disease-chemoanatomic, ultrastructural, and metabolic studies. J. Comp. Neurol. 370(2):1996;203-230.
42. Olson L., Backman L., Ebendal et al T. Role of growth factors in degeneration and regeneration in the central nervous system; clinical experiences with NGF in Parkinson's and Alzheimer's diseases. J. Neurol. 241:1994;512-515.
43. Krewson C.E., Saltzman W.M. Nerve growth factor delivery and cell aggregation enhance choline acetyltransferase activity after neural transplantation. Tissue Eng. 2(3):1996;183-196.
44. Ito Y., Inoue M., Imanishi Y. Cell growth on immobilized cell growth factor. 6. Enhancement of fibroblast cell growth by immobilized insulin and/or fibronectin. J. Biomed. Mat. Res. 27:1993;901-907.
45. Carbonetto S.T., Gruver M.M., Turner D.C. Nervefiber growth on defined hydrogel substrates. Science. 216:1982;897-899.
46. Kuhl P.R., Griffith-Cima L.G. Tethered epidermal growth factor as a paradigm for growth factor-induced stimulation from the solid phase. Nature Med. 2(9):1996;1022-1027.
47. Ito Y., Liu S.Q., Imanishi Y. Enhancement of cell growth on growth factor-immobilized polymer film. Biomaterials. 12:1991;449-453.
48. Ito Y., Zheng J., Imanishi Y. Novel biomaterials immobilized with biosignal molecules. Mat. Sci. Eng. C2:1994;67-72.
49. Winn S.R., Lindner M.D., Lee A., Haggett G., Francis J.M., Emerich D.F. Polymer-encapsulated genetically modified cells continue to secrete human nerve growth factor for over one year in rat ventricles: behavioral and anatomical consequences. Exp. Neurol. 140:1996;126-138.
50. Rosenberg M.B., Friedmann T., Robertson et al R.C. Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science. 242:1988;1575-1578.
51. Dai W., Saltzman W.M. Fibroblast aggregation by suspension with conjugates of poly(ethlyene glycol) and RGD. Biotechnol. Bioeng. 50:1996;349-356.
52. Dai W., Belt J., Saltzman W.M. Cell-binding peptides conjugate to poly(ethylene glycol) promote neural cell aggregation. Biotechnology. 12:1994;797-801.
53. W. Dai, Ph.D. thesis, Enhancement of cell aggregation and function by polymers, The Johns Hopkins University, 1996, p. 228.
54. Driever W., Nusslein-Volhard C. A gradient of bicoid protein in drosophila embryos. Cell. 54:1988;83-93.